{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:06:45Z","timestamp":1769123205284,"version":"3.49.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating acute and long-term toxicity in cancer patients. We sought to describe the landscape of CIPN research funded by the National Institutes of Health (NIH) and identify gaps and opportunities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the NIH Query View Report system, we identified 180 competitive grants between 2014-2023 containing text pertaining to CIPN in the Abstract or Specific Aims. These were categorized as preclinical, clinical, or both and described by preclinical model, clinical population, CIPN assessments, and\/or clinical trial design. We identified 5 additional NCI-funded trials through the NCORP network pertaining to CIPN.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 185 studies, 125 were preclinical, 56 clinical, and 4 both preclinical\/clinical. Among preclinical studies, most studies used rodent CIPN models, of which 17% were tumor-bearing. Most preclinical studies investigated paclitaxel; none studied newer immune therapies. The 60 clinical studies were 53% observational and 47% interventional, focusing most frequently on breast cancer, unspecified cancers, and colorectal cancer diagnoses. Overall, 8% included patients &amp;lt;18\u2009years, whereas a higher proportion included those 18-39 (85%), 40-64 (90%), and \u226565 (92%). Among 28 interventional trials, studies investigated behavioral interventions (39%), pharmacological agents (32%), and devices (29%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The number of CIPN grants awarded by NIH since 2014 represents a substantial investment, but critical gaps and opportunities remain. Preclinically, novel strategies to mimic human CIPN may improve translatability. Important gaps in CIPN-associated cancer diagnoses and therapy exposures, including novel agents, would benefit from future research. Also, clinical studies are needed in young patients with potential long-term CIPN.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncics\/pkaf039","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T15:18:58Z","timestamp":1745248738000},"source":"Crossref","is-referenced-by-count":3,"title":["Chemotherapy-induced peripheral neuropathy research: a National Institutes of Health (NIH) grant portfolio analysis (2014-2023)"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1771-9287","authenticated-orcid":false,"given":"Rachel D","family":"Altshuler","sequence":"first","affiliation":[{"name":"Division of Cancer Prevention, National Cancer Institute, National Institutes of Health , Rockville, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0472-4079","authenticated-orcid":false,"given":"Lori M","family":"Minasian","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention, National Cancer Institute, National Institutes of Health , Rockville, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3890-9454","authenticated-orcid":false,"given":"Catherine A","family":"Schweppe","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention, National Cancer Institute, National Institutes of Health , Rockville, MD,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-396X","authenticated-orcid":false,"given":"Nina S","family":"Kadan-Lottick","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention, National Cancer Institute, National Institutes of Health , Rockville, MD,","place":["United States"]},{"name":"Department of Oncology Cancer Prevention and Control Program, Georgetown University Lombardi Comprehensive Cancer Center , Washington, DC,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"2025061510460950000_pkaf039-B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11864-021-00926-0","article-title":"Updates in the treatment of chemotherapy-induced peripheral neuropathy","volume":"23","author":"Mezzanotte","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"2025061510460950000_pkaf039-B2","doi-asserted-by":"publisher","first-page":"151499","DOI":"10.1016\/j.soncn.2023.151499","article-title":"Real-life experiences of chemotherapy-induced peripheral neuropathy in patients with cancer: a qualitative meta-synthesis study","volume":"39","author":"Kim","year":"2023","journal-title":"Semin Oncol Nurs"},{"key":"2025061510460950000_pkaf039-B3","doi-asserted-by":"publisher","first-page":"112671","DOI":"10.1016\/j.biopha.2022.112671","article-title":"Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: an update","volume":"147","author":"Desforges","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2025061510460950000_pkaf039-B4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk","volume":"159","author":"Bao","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2025061510460950000_pkaf039-B5","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","article-title":"Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials","volume":"34","author":"Hershman","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025061510460950000_pkaf039-B6","doi-asserted-by":"publisher","first-page":"6088","DOI":"10.3390\/cancers14246088","article-title":"Neurological complications of conventional and novel anticancer treatments","volume":"14","author":"Alberti","year":"2022","journal-title":"Cancers"},{"key":"2025061510460950000_pkaf039-B7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ygyno.2024.04.021","article-title":"Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: a substudy of the GINECO Vivrovaire study","volume":"187","author":"Zenatri","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2025061510460950000_pkaf039-B8","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/jco.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025061510460950000_pkaf039-B9","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1002\/cncr.33108","article-title":"Chemotherapy-induced peripheral neuropathy: identifying the research gaps and associated changes to clinical trial design","volume":"126","author":"St Germain","year":"2020","journal-title":"Cancer"},{"key":"2025061510460950000_pkaf039-B10","author":"National Institutes of Health"},{"key":"2025061510460950000_pkaf039-B11","doi-asserted-by":"publisher","first-page":"1264668","DOI":"10.3389\/fvets.2023.1264668","article-title":"Preclinical research in paclitaxel-induced neuropathic pain: a systematic review","volume":"10","author":"Bacalhau","year":"2023","journal-title":"Front Vet Sci"},{"key":"2025061510460950000_pkaf039-B12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/bja\/aex229","article-title":"Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review","volume":"119","author":"Flatters","year":"2017","journal-title":"Br J Anaesth. 2017\/10\/01"},{"key":"2025061510460950000_pkaf039-B13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/jns.12544","article-title":"Targeting translation: a review of preclinical animal models in the development of treatments for chemotherapy-induced peripheral neuropathy","volume":"28","author":"White","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"2025061510460950000_pkaf039-B14","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1158\/0008-5472.Can-19-2331","article-title":"Cancer exacerbates chemotherapy-induced sensory neuropathy","volume":"80","author":"Housley","year":"2020","journal-title":"Cancer Res"},{"key":"2025061510460950000_pkaf039-B15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12974-022-02566-z","article-title":"Sensory neuron dysfunction in orthotopic mouse models of colon cancer","volume":"19","author":"Balogh","year":"2022","journal-title":"J Neuroinflammation"},{"key":"2025061510460950000_pkaf039-B16","doi-asserted-by":"publisher","first-page":"e29550","DOI":"10.1002\/pbc.29550","article-title":"Newly identified chemotherapy-induced peripheral neuropathy in a childhood cancer survivorship clinic","volume":"69","author":"Rodwin","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"2025061510460950000_pkaf039-B17","doi-asserted-by":"publisher","first-page":"637593","DOI":"10.3389\/fphar.2021.637593","article-title":"Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: a single center cross-sectional study","volume":"12","author":"Selvy","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025061510460950000_pkaf039-B18","doi-asserted-by":"publisher","first-page":"1134436","DOI":"10.3389\/fimmu.2023.1134436","article-title":"Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years","volume":"14","author":"Ruggiero","year":"2023","journal-title":"Front Immunol"},{"key":"2025061510460950000_pkaf039-B19","doi-asserted-by":"publisher","first-page":"1015746","DOI":"10.3389\/fmolb.2022.1015746","article-title":"Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients","volume":"9","author":"Tay","year":"2022","journal-title":"Front Mol Biosci"},{"key":"2025061510460950000_pkaf039-B20","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/s2352-4642(18)30236-0","article-title":"Peripheral neuropathy in children and adolescents treated for cancer","volume":"2","author":"Bjornard","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"2025061510460950000_pkaf039-B21","author":"National Cancer Institute"},{"key":"2025061510460950000_pkaf039-B22","author":"National Institutes of Health","year":"2024"},{"key":"2025061510460950000_pkaf039-B23","author":"National Institutes of Health"},{"key":"2025061510460950000_pkaf039-B24","author":"National Institutes of Health"},{"key":"2025061510460950000_pkaf039-B25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/jnci\/djz011","article-title":"The National Cancer Institute clinical trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy","volume":"111","author":"Dorsey","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025061510460950000_pkaf039-B26","doi-asserted-by":"publisher","first-page":"113154","DOI":"10.1016\/j.expneurol.2019.113154","article-title":"Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy","volume":"325","author":"Bruna","year":"2020","journal-title":"Exp Neurol"},{"key":"2025061510460950000_pkaf039-B27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/toxics9110300","article-title":"Considerations for a reliable in vitro model of chemotherapy-induced peripheral neuropathy","volume":"9","author":"Eldridge","year":"2021","journal-title":"Toxics"},{"key":"2025061510460950000_pkaf039-B28","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann Oncol"},{"key":"2025061510460950000_pkaf039-B29","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.4103\/jfmpc.jfmpc_580_21","article-title":"A review of the neurological complications of breast cancer","volume":"11","author":"Hekmatnia","year":"2022","journal-title":"J Family Med Prim Care"},{"key":"2025061510460950000_pkaf039-B30","author":"NCI Surveillance Epidemiology and End Results Program (SEER)","year":"2024"},{"key":"2025061510460950000_pkaf039-B31","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00520-013-1766-y","article-title":"Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study","volume":"21","author":"Gewandter","year":"2013","journal-title":"Support Care Cancer"},{"key":"2025061510460950000_pkaf039-B32","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/noajnl\/vdab107","article-title":"A review of neurotoxicities associated with immunotherapy and a framework for evaluation","volume":"3","author":"Burton","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2025061510460950000_pkaf039-B33","doi-asserted-by":"publisher","first-page":"101509","DOI":"10.1016\/j.gore.2024.101509","article-title":"Exploring social determinants of health on chemotherapy-induced peripheral neuropathy severity in ovarian cancer: an integrative review","volume":"55","author":"Odii","year":"2024","journal-title":"Gynecol Oncol Rep"},{"key":"2025061510460950000_pkaf039-B34","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.1002\/cam4.4328","article-title":"Chemotherapy-induced peripheral neuropathy in African American cancer survivors: risk factors and quality of life outcomes","volume":"10","author":"Trendowski","year":"2021","journal-title":"Cancer Med"},{"key":"2025061510460950000_pkaf039-B35","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1158\/1078-0432.Ccr-16-3224","article-title":"Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer","volume":"23","author":"Dolan","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025061510460950000_pkaf039-B36","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"2025061510460950000_pkaf039-B37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00520-023-08301-5","article-title":"Considerations for establishing and maintaining international research collaboration: the example of chemotherapy-induced peripheral neurotoxicity (CIPN): a white paper","volume":"32","author":"Alberti","year":"2024","journal-title":"Support Care Cancer"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkaf039\/62961458\/pkaf039.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/3\/pkaf039\/62961458\/pkaf039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/3\/pkaf039\/62961458\/pkaf039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T14:46:15Z","timestamp":1749998775000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkaf039\/8117010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkaf039","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,21]]},"article-number":"pkaf039"}}